Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of BR9004 vs BR9004-1 (Zytiga) in Healthy Male Volunteers
NCT04889651Phase 1Completed
- Sponsor
- Boryung
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abiraterone in prostate cancer (PCa), sponsored by Boryung. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve to the Last Quantifiable Concentration. Started Apr 2021; status: completed.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04889651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889651.